Amneal Pharmaceuticals, Inc.
General ticker "AMRX" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $2.7B (TTM average)
Amneal Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 64.1%.
Estimated limits based on current volatility of 1.5%: low 12.96$, high 13.36$
Factors to consider:
- Total employees count: 8100 (+5.2%) as of 2024
- Top business risk factors: Product development risks, Regulatory and compliance, Supply chain disruptions, Acquisition/divestiture risks, Geopolitical risks
- Current price 39.2% above estimated high
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.99$, 10.55$]
- 2025-12-31 to 2026-12-31 estimated range: [5.34$, 9.64$]
Financial Metrics affecting the AMRX estimates:
- Positive: with PPE of 13.5 at the end of fiscal year the price was low
- Positive: 7.54 < Operating profit margin, % of 9.24
- Positive: 6.63 < Operating cash flow per share per price, % of 12.23
- Negative: Shareholder equity ratio, % of -3.12 <= 19.35
- Positive: -4.41 < Investing cash flow per share per price, % of -2.61
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of -1.67 <= -0.18
Short-term AMRX quotes
Long-term AMRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,945.60MM | $2,407.42MM | $2,698.20MM |
| Operating Expenses | $2,040.53MM | $2,203.04MM | $2,448.87MM |
| Operating Income | $-94.93MM | $204.37MM | $249.33MM |
| Non-Operating Income | $-153.20MM | $-244.64MM | $-304.34MM |
| Interest Expense | $158.38MM | $210.63MM | $258.60MM |
| R&D Expense | $195.69MM | $163.95MM | $190.71MM |
| Income(Loss) | $-248.13MM | $-40.27MM | $-55.01MM |
| Taxes | $6.66MM | $8.45MM | $18.86MM |
| Profit(Loss)* | $-129.99MM | $-83.99MM | $-116.89MM |
| Stockholders Equity | $298.42MM | $19.78MM | $-109.27MM |
| Inventory | $530.74MM | $581.38MM | $612.45MM |
| Assets | $3,799.34MM | $3,472.57MM | $3,501.45MM |
| Operating Cash Flow | $65.10MM | $345.58MM | $295.10MM |
| Capital expenditure | $90.59MM | $69.19MM | $74.99MM |
| Investing Cash Flow | $-174.31MM | $-69.19MM | $-63.00MM |
| Financing Cash Flow | $-106.62MM | $-212.57MM | $-211.79MM |
| Earnings Per Share** | $-0.86 | $-0.48 | $-0.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.